Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders
Recruiting in Palo Alto (17 mi)
MR
Overseen byMichael R Grandner, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: University of Arizona
Stay on Your Current Meds
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is a viable adjunctive treatment of substance use treatments.
Research Team
MR
Michael R Grandner, PhD
Principal Investigator
University of Arizona
Eligibility Criteria
Inclusion Criteria
Be able to provide informed consent, assessed by the study clinician
Be able to speak, read and write fluently in English, assessed by the study clinician
Be committed to completion of the study. The subject will need to attest to availability for 10 to 15 treatments over a 5 to 8 day period for the treatment protocol.
See 2 more
Treatment Details
Interventions
- Nexalin Therapy (Trans-cranial Electrical Stimulation)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TES TreatmentExperimental Treatment1 Intervention
Where subject is randomized to TES.
Group II: TES-SHAM TreatmentPlacebo Group1 Intervention
Where subject is randomized to a SHAM condition
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Arizona
Lead Sponsor
Trials
545
Recruited
161,000+
Dr. Richard Carmona
University of Arizona
Chief Medical Officer since 2021
MD, University of Arizona
Dr. Evan Unger
University of Arizona
Chief Executive Officer since 2021
PhD in Medical Imaging, University of Arizona
Carrier Clinic
Collaborator
Trials
2
Recruited
120+